Jesse Erasmus
Director, Virology HDT Bio
Seminars
Wednesday 27th May 2026
Redefining Non-Hepatic RNA Delivery to Unlock Safer Self-Amplifying RNA at Clinically Relevant Doses
1:30 pm
- Demonstrating how extra-hepatic delivery overcomes dose-limiting toxicities, enabling unprecedented clinical dose escalation of self-amplifying RNA without Grade 3 adverse events
- Connect RNA design, formulation, and process decisions to myocarditis risk, using integrated clinical, preclinical, and mechanistic data to explain why safety failures occur
- Translate mechanistic insight into actionable delivery strategies, showing how non-hepatic targeting mitigates innate immune activation and supports repeat dosing in next-generation RNA therapeutics
Wednesday 27th May 2026
Panel: Comparing Delivery Architectures to Match Modalities to Indication Needs
4:15 pm
- Debate core trade-offs including tropism, immunogenicity, manufacturability, payload size, and dosing frequency across LNP, AAV, and novel options
- Determine best-fit delivery platforms for CNS, immune modulation, oncology, hepatic, and neuromuscular indications
- Address LNP partnership models that support predictable GMP supply and scalable therapeutic development
